Gonda I
Department of Pharmacy, University of Sydney, Australia.
Crit Rev Ther Drug Carrier Syst. 1990;6(4):273-313.
Inhaled therapeutic and diagnostic aerosols are examples of targeted delivery systems: they achieve high concentration in the respiratory tract (the usual target organ with these systems) while appearing in low concentrations in other parts of the human body. Development and use of inhalation aerosols requires an appreciation of the properties of these dynamic systems and the ways in which they interact with the anatomically and pathophysiologically complex human respiratory tract. The amounts of aerosol particles, or droplets, initially deposited at various sites in the respiratory tract will determine the intensity of local effects as well as the rate of clearance of these materials from the respiratory lumen. This activity can be modulated by suitable formulation intervention, such as presentation of the active agent in a slow releasing form carrier. Extension of duration of action of inhaled drugs by such means could be possible. As more discriminating methods for location of receptors and for the following of the fate of inhaled drugs and their carriers are becoming available, the ultimate potential for improvement of selective toxicity of agents used in pulmonary therapy by direct delivery into the respiratory tract can be critically evaluated.
它们在呼吸道(这些系统的通常靶器官)中达到高浓度,而在人体其他部位则以低浓度出现。吸入气雾剂的开发和使用需要了解这些动态系统的特性以及它们与解剖学和病理生理学复杂的人类呼吸道相互作用的方式。最初沉积在呼吸道各个部位的气溶胶颗粒或液滴的数量将决定局部作用的强度以及这些物质从呼吸腔清除的速率。这种活性可以通过合适的制剂干预来调节,例如以缓释形式载体呈现活性剂。通过这种方式延长吸入药物的作用持续时间是可能的。随着用于定位受体以及追踪吸入药物及其载体命运的更具区分性的方法不断涌现,可以对通过直接递送至呼吸道来提高肺部治疗所用药物的选择性毒性的最终潜力进行严格评估。